Metabolic marker profiling of circulating tumour cells in NSCLC patients treated with osimertinib: focus on MCT1 and MCT4
Therapeutic Advances in Medical Oncology · 2026-02 · 18
DOI: 10.1177/17588359261416422 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 15.02.2026. Verfasst von Karolina Mangani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biochemistry and Metastatic Signaling, Department of Biology, University of Patras, Patras, Greece. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Research Council of the University of Patras, general secretariat for research and innovation, nextgenerationeu.
Abstract (Originalsprache)
Background
Monocarboxylate transporters (MCTs) facilitate lactate transfer and support cancer cell survival and metastasis. MCT1 and MCT4 expression has been associated with poor prognosis and resistance to therapy with tyrosine kinase inhibitors.
Objectives
This pilot study examined the relevance of MCT1 and MCT4 expression in circulating tumour cells (CTCs) isolated from non-small cell lung cancer (NSCLC) patients during osimertinib treatment through single-cell analysis.
Design
Fifty-three NSCLC patients were enrolled at three different time points: baseline ( n = 53), post-first cycle ( n = 20) and progressive disease (PD; n = 21), to evaluate MCT1 and MCT4 expression in patients’ samples.
Methods
CTCs were isolated with the ISET platform. MCT1/MCT4 expression was assessed using immunofluorescence triple staining experiments and confocal laser scanning microscopy.
Results
CTCs were detected in 75% (40/53), 40% (8/20) and 29% (6/21) of patients at baseline, post-first cycle and PD, respectively. Among cytokeratin (CK)-positive patients, MCT1 was overexpressed at all time points in a significant percentage: 67% (18/27) at baseline, 57% (4/7) at post-first cycle and 50% (2/4) at PD. Similarly, MCT4 was overexpressed in 55% (16/29), 50% (2/4) and 60% (3/5) of cases, respectively. Statistical analysis revealed that the (CK+MCT1−CD45−) phenotype was associated with worse progression-free survival [PFS; log rank, p = 0.041, hazard ratio (HR) = 1.971] and overall survival (log rank, p = 0.028; HR = 2.288) of the patients. Conversely, the presence of ⩾3 MCT4+ CTCs was correlated with poorer PFS (log rank, p = 0.042, HR = 4.189). Significant inverse correlations were observed between MCT1 and MCT4 expression, implying their distinct biological roles.
Conclusion
MCT1 and MCT4 are overexpressed in CTCs from NSCLC patients, supporting their potential as prognostic biomarkers and therapeutic targets.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Biochemistry and Metastatic Signaling, Department of Biology, University of Patras, Patras, Greece.
- Analysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Athens, Greece.
- Hellenic Oncology Research Group, Athens, Greece.
- Department of Medical Oncology, University General Hospital of Larissa, Larissa, Greece.
- Laboratory of Biochemistry and Metastatic Signaling, Department of Biology, University of Patras, Patras 26504, Greece.
ORCID-Profile: Karolina Mangani, Evangelia Pantazaka, Evi Lianidou, Vassilis Georgoulias, Athanasios Kotsakis, Athina Markou, Galatea Kallergi
Förderung
- Research Council of the University of Patras
- general secretariat for research and innovation
- nextgenerationeu
- Hellenic Precision Medicine Network
Zitieren
APA
Mangani, K., Pantazaka, E., Lianidou, E., Georgoulias, V., Kotsakis, A., Markou, A., & Kallergi, G. (2026). Metabolic marker profiling of circulating tumour cells in NSCLC patients treated with osimertinib: focus on MCT1 and MCT4. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261416422
Vancouver
Mangani K, Pantazaka E, Lianidou E, Georgoulias V, Kotsakis A, Markou A, et al. Metabolic marker profiling of circulating tumour cells in NSCLC patients treated with osimertinib: focus on MCT1 and MCT4. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261416422
BibTeX
@article{Mangani2026,
author = {Mangani, Karolina and Pantazaka, Evangelia and Lianidou, Evi and Georgoulias, Vassilis and Kotsakis, Athanasios and Markou, Athina and Kallergi, Galatea},
title = {Metabolic marker profiling of circulating tumour cells in NSCLC patients treated with osimertinib: focus on MCT1 and MCT4},
journal = {Therapeutic Advances in Medical Oncology},
year = {2026},
volume = {18},
doi = {10.1177/17588359261416422}
}
EUVIMED